Trident Lifeline Limited reported robust Q1FY26 financial results. Revenue increased by 27% to ₹1,935.48 lakh, EBITDA grew 20% to ₹546.36 lakh, and profit after tax rose 15% to ₹347.59 lakh. The company operates in 43 countries with 1,035 registered export products and 2,329 in process. Trident maintains a diverse product portfolio of 3,364 items across various therapeutic categories. Management expressed satisfaction with the performance and anticipates continued growth driven by organic and inorganic expansion strategies.